Overview
ELDN market data
Price History
ELDN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.56 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.99 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.35 – $4.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $289.4 · P/B 0.83.
Company news
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For TuesdayBenzinga · Jul 21, 2026, 3:14 PM
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 21, 2026, 11:58 AM
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12Benzinga · Jul 21, 2026, 11:53 AM
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed StrategyBenzinga · Jul 1, 2026, 1:40 PM
Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney TransplantationBenzinga · Jun 25, 2026, 11:15 AM
8-K filing — Eledon Pharmaceuticals, Inc. (ELDN)SEC EDGAR · Jun 22, 2026, 9:00 PM
Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026Benzinga · Jun 22, 2026, 11:20 AM
Eledon Pharmaceuticals Announces Updated Results From A Trial Evaluating Tegoprubart, Its Investigational Anti-CD40L Antibody; All 12 Patients Treated In The Study Showed Rapid Improvement In Glycemic ControlBenzinga · Jun 8, 2026, 11:30 AM
Eledon Pharmaceuticals To Present Updated Data From Investigator-Initiated Study At American Diabetes Association 86th Scientific SessionsBenzinga · Jun 4, 2026, 8:35 PM
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND SubmissionBenzinga · May 27, 2026, 11:31 AM